Compare Recursion Pharmaceuticals Inc (RXRX) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B), while Consumer Discretionary Select Sector SPDR Fund trades at $112.79. The key difference: Consumer Discretionary Select Sector SPDR Fund is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | XLY | |
|---|---|---|
Market Cap | $1.74B | — |
Sector | Health | — |
52-Week High | $6.79 | $124.52 |
52-Week Low | $2.84 | $105.64 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
XLY trades at $113.99, down 0.8% today amid bearish technical signals with 18 sell indicators versus 3 buy signals. The ETF maintains 100% analyst buy consensus despite missing key valuation metrics. Recent news highlights consumer discretionary sector opportunities, with XLY positioned as a potential sleeper ETF for Q3 2026 given resilient consumer spending trends and economic conditions.
The outlook remains cautiously optimistic with strong analyst support, though technical weakness and sector concentration risks warrant monitoring. Upside potential exists from consumer spending resilience and economic broadening, while downside risks include market volatility and inflationary pressures affecting discretionary purchases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
